GILD – Market expectations are for Uniform ROA to fall to new lows, and management may have concerns about oncology and partnerships

December 16, 2021

Gilead Sciences (GILD) currently trades well below corporate averages relative to Uniform earnings, with a 9.5x Uniform P/E (Fwd. V/E’).

At these levels, markets are pricing in expectations for Uniform ROA to fall to new lows of 10%, accompanied by 7% Uniform asset growth.

Meanwhile, analysts expect Uniform ROA to decline to 22% by 2022, accompanied by 20% Uniform asset growth.

If sustained going forward, these levels would imply a stock price closer to $338, representing significant potential equity upside for the firm.

However, the firm’s most recent earnings call suggests management may have concerns about oncology and partnerships.

You don’t have access to the Valens Research Premium Application.

To get access to our best content including the highly regarded Conviction Long List and Market Phase Cycle macro newsletter, please contact our Client Relations Team at 630-841-0683 or email

Please fill out the fields below so that our client relations team can contact you

Or contact our Client Relationship Team at 630-841-0683